September 30th

8:00-8:15  Registration

8:15:8:20  Opening Session - Brazilian Society of Hepatology President
          Edison Parise (Brazil)

8:20 – 9:50  Session I:  Emerging Mechanisms of ALPD
            - Autophagy and ALD
              Xiao-Ming Yin (USA)
            - Combination therapy: new hope for alcoholic hepatitis (AH)?
              Bin Gao (USA)
            - Cystic fibrosis-like changes in the early phase of pancreatitis
              Peter Hegyi (Hungary)
            - Inflammasomes in ASH and NAFLD
              Gyongi Szabo (USA)
            - Discussion (10’)

9:50-10:20  State-of-the-Art Lecture I – “Chronic ASH vs. alcoholic hepatitis”
            Ramon Bataller (USA)

10:20-10:50 – Break and Poster Viewing

10:50-12:20  Session II: Synergistic Interactions of ASH and NAFLD
             - Notch Signaling and M1 Macrophage Activation in Obesity-alcohol Synergism?
               Jun Xu (USA)
             - Synergy between NAFLD and AFLD and potential biomarkers
               Raj Lakshman (USA)
             - Genetic polymorphisms and oxidative stress in NAFLD
               Claudia Oliveira (Brazil)
             - Nutrition therapy for metabolic syndrome
               Puneet Puri (USA)
             - Discussion (10’)

12:20-12:50  State-of-the-Art Lecture II – “Update on the therapy of alcoholic hepatitis”
            Philippe Mathurin (France)

12:50-13:50  Hot Topics
            - New therapeutic targets for steatohepatitis
              Arun Sayal (USA)
            - A reprogramming-based approach to treating liver fibrosis
              Holger Willenbring (USA)

13:50-14:30  Poster viewing

14:30-16:00  Session III: Cutting Edge in Liver fibrosis
             - What is new in liver fibrosis related to alcohol or virus?
               Detlef Schuppan (Germany)
             - Liver fibrosis reversal mechanism
               Tatiana Kissevela (USA)
             - Epigenetic regulation of liver fibrosis
               Derek Mann (UK)
             - Morphogen-related therapeutic targets for liver fibrosis
               Hidekazu Tsukamoto (USA)
             - Discussion (10’)

16:00-16:30  State-of-the-Art Lecture III – “New developments in treatment of liver fibrosis caused by alcohol, obesity and HCV”
16:30-17:00 - **Break and Poster Viewing**

**Session IV: Case discussions on ALPD complications**
- Ascites and non-SBP infection
  Adrian Gadano (Argentina)
- Ascites and jaundice
  André Siqueira Matheus (SP)
- Upper gastrointestinal bleeding and encephalopathy
  Javier Brahms (Chile)

18:30-19:00 **Evening Seminar - “New Insights on Treatments of HCC”**
Josep Llovet (USA)

20:00 **Opening Session of the Brazilian Hepatology Meeting**

October 1st

08:00-9:30 **Session V: Alcohol and Liver and Pancreatic Cancer**
- Alcohol on liver and pancreatic cancer
  Sam Zakhari (USA)
- Gut microbiota and HCC
  Robert Schwabe (USA)
- Stem cells and HCC
  Claudio Tiribelli (Italy)
- Pancreatic stellate cells and pancreatic cancer
  Atsushi Masamune (Japan)
- Discussion (10’)

9:30-9:45 **Special Remarks - NIAAA Deputy Director**
Kenneth Warren (USA)

9:45-9:50 **Announcement for Future ISALPD/C**
Hide Tsukamoto (USA)

9:50-10:30 **Break and Poster Viewing (with presentation of selected winners)**

10:30-12:00 **Session VI: Management of HCC and Liver Transplantation**
- Proangiogenic factors in the development of HCC in alcoholic cirrhosis
  Helana Cortez Pinto (Portugal)
- Management of alcohol recurrence before and after liver transplantation
  Claudio Marrone (Brazil)
- Management of hepatitis C in the context of liver transplantation
  Marina Berenguer (Spain)
- New drugs for hepatocellular carcinoma
  Josep Llovet (USA)
- Discussion (10’)

David Brenner (USA)